CELLINK publishes quarterly report for the third quarter

CELLINK AB ("CELLINK" or "Company") publishes quarterly report for the period 1st of March 2017 – 31th of May 2017 and the results for the first nine months. The report is available on the company's website: http://cellink.com/investor-relations/. This press release presents a summary of the report.

Quarter 3 (Q3), March 1st, 2016 - May 31st, 2017

  •        Operating revenues amounted to 5,162 kSEK
  •        Net sales of 3,103 kSEK
  •        Operating profit before depreciation, EBITDA amounted to -441 kSEK
  •        Operating profit amounted to -537 kSEK
  •        Profit before tax amounted to -566 kSEK
  •        Earnings per share amounted to -0,082 SEK in the 3rd quarter
  •        Cash flow from operating activities in the quarter amounted to -1,460 kSEK

9 months, September 1st, 2016 – May 31st, 2017

  •        Operating income amounted to 13,036 kSEK
  •        Net sales of 8 750 kSEK
  •        Operating profit before depreciation, EBITDA amounted to 242 kSEK, which corresponds to an EBITDA margin of 1.9%
  •        Operating profit amounted to 55 kSEK
  •        Profit before tax amounted to -45 kSEK
  •        Earnings per share amounted to SEK -0
  •        Cash flow from operating activities during the period amounted to 1,024 kSEK

Events in the third quarter (March 2017 - May 2017)

  • On March 17, the company appointed an Advisory Board to assist the company in strategic matters

Events after the end of the period

  •        On June 9, the company announced that it received orders in connection with new distribution agreements
  •        On July 10, CELLINK signed a distribution agreement with Thermo Fisher Scientific ANZ
  •        On July 12, CELLINK conducted a directed share issue of B shares of 30 MSEK        

For further information, please contact:

Erik Gatenholm, CEO                                     Gusten Danielsson, CFO

Phone: +46 73 267 00 00                             Phone: +46 70 991 86 04

E-mail: [email protected]                                E-mail: [email protected]

Important information

This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on July 19, 2017 at. 08:30 CET.


CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. Mangold Fondkommission AB, tel: +46 (0) 8 5030 1550, is the Company's Certified Adviser.

Latest press releases